Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | VHL | P40337 | 1/20 | 0.34 |
| ▸ | ELOC | Q15369 | 1/20 | 0.34 |
| ▸ | ELOB | Q15370 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28312128 | 0.83 | CYP4A11 (0.48) | TSHRPPARACYP3A4CA12CA1 | |
| SCHEMBL27531154 | 0.80 | LTA4H (0.38) | LTA4HTSHRNOS3NOS1PPARG | |
| SCHEMBL31541709 | 0.80 | LTA4H (0.38) | LTA4HTSHRNOS3NOS1PPARG | |
| SCHEMBL8955219 | 0.80 | CA12 (0.35) | TSHRPPARGPPARACYP3A4PPARD | |
| SCHEMBL3149031 | 0.79 | ABCB11 (0.39) | TSHRCYP3A4CA12CA2CA4 | |
| SCHEMBL9008790 | 0.79 | TDP1 (0.50) | TSHRCA2CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL4738416 | 0.78 | ACHE (0.50) | LTA4HTSHRNOS3NOS1PPARG | |
| SCHEMBL19640126 | 0.77 | TTR (0.37) | TSHRCA1CA2CYP1A2CYP2D6 | |
| SCHEMBL7328733 | 0.77 | TSHR (0.39) | TSHRCA2CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL8954887 | 0.77 | IDO1 (0.42) | ERN1CA2CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109415353-B | Pegylated carfilzomib compounds | 美国安进公司 | 2023-01-10 | — | — | CN | disclosed |
| EP-3464277-B1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-11077198-B2 | Pegylated carfilzomib compounds | AMGEN INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11077198-B2 | Pegylated carfilzomib compounds | AMGEN INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200376131-A1 | Pegylated Carfilzomib Compounds | AMGEN INC. (US) | 2020-12-03 | — | — | US | disclosed |
| US-20200376131-A1 | Pegylated Carfilzomib Compounds | AMGEN INC. (US) | 2020-12-03 | — | — | US | disclosed |
| US-10675353-B2 | Pegylated carfilzomib compounds | AMGEN INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10675353-B2 | Pegylated carfilzomib compounds | AMGEN INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200069808-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2020-03-05 | — | — | US | disclosed |
| US-20200069808-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2020-03-05 | — | — | US | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| EP-1650565-B1 | SURFACE OF BASE MATERIAL BEING INHIBITED IN NON-SPECIFIC ADSORPTION | JSR CORP (JP) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008136756-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
| WO-2007025776-A2 | CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | WO | disclosed |
| US-20060240438-A1 | Surface of base material being inhibited in non-specific adsorption | JSR CORPORATION (JP) | 2006-10-26 | — | — | US | disclosed |
| EP-1650565-A1 | SURFACE OF BASE MATERIAL BEING INHIBITED IN NON-SPECIFIC ADSORPTION | Tokyo University of Science, Educational Foundation (JP) | 2006-04-26 | — | — | EP | disclosed |
| WO-2006027211-A1 | 2,4-SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-03-16 | — | — | WO | disclosed |
| EP-1601384-A1 | METHODS OF RADIOFLUORINATION OF BIOLOGICALLY ACTIVE VECTORS | Amersham Health AS (NO) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004080492-A1 | METHODS OF RADIOFLUORINATION OF BIOLOGICALLY ACTIVE VECTORS | AMERSHAM HEALTH AS (NO) | 2004-09-23 | — | — | WO | disclosed |
| US-6111084-A | Fuopeptide mimetics | THE SCRIPPS RESEARCH INSTITUTE (US) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099195-A1 | Therapeutic Compounds 570 | OPRL1, OPRK1, OPRM1 | LTA4H 810/4885TSHR 1066/4885NOS3 852/4885 |
| US-20200376131-A1 | Pegylated Carfilzomib Compounds | FCGRT, EPOR, MCL1 | LTA4H 3016/4885TSHR 2276/4885NOS3 1494/4885 |
| US-11077198-B2 | Pegylated carfilzomib compounds | FCGRT, EPOR, MCL1 | LTA4H 3016/4885TSHR 2276/4885NOS3 1494/4885 |
| US-10675353-B2 | Pegylated carfilzomib compounds | FCGRT, EPOR, MCL1 | LTA4H 3016/4885TSHR 2276/4885NOS3 1494/4885 |
| US-20200069808-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | FCGRT, EPOR, MCL1 | LTA4H 3016/4885TSHR 2276/4885NOS3 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.